Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inhaled molgramostim pilot trial in antibiotic-resistant pulmonary NTM infection
2017-003374-14Phase 2Completed
- Sponsor
- Savara
- Start
- Dec 2017
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sargramostim in Pulmonary mycobacteriosis, Mycobacterium avium lung disease and Mycobacterium abscessus lung disease, sponsored by Savara. Primary endpoint: Sputum culture conversion. Started Dec 2017; status: completed.
02
Drugs
sargramostim
03
Conditions
Pulmonary mycobacteriosisMycobacterium avium lung diseaseMycobacterium abscessus lung disease
Beyond the preview
Go deeper on 2017-003374-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-003374-14.